Skip to content

The Impact of an Epidural Ropivacaine-Neostigmine Injection for Perineal Analgesia at the End of Labor.

The Impact of an Epidural Ropivacaine-Neostigmine Injection for Perineal Analgesia at the End of Labor, on Either Immediate Postpartum Perineal Pain or Development of Chronic Perineal Pain After Vaginal Delivery.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00407290
Enrollment
60
Registered
2006-12-05
Start date
2006-03-31
Completion date
2006-10-31
Last updated
2006-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy, Vaginal Delivery

Keywords

pregnancy, vaginal delivery

Brief summary

Perineal pain after childbirth occurs in the majority of women (with or without episiotomy). Perineal pain can become source of chronic pain in 9%-12% of the cases. Neostigmine a cholinesterase inhibitor at a dose of 500µg combined with Sufentanil or Ropivacaine (=local anaesthetic) is an analgesic. The goal of this study is to examine the effect of the use of epidural Neostigmine for perineal analgesia at the end of the labor on acute pain and on the development of chronic pain post partum.

Detailed description

The goal of epidural analgesia during labour is to obtain an analgesia with a minimum of motor block. Absence of motor block at the time of the childbirth allows to decrease the rate of instrumentation (forceps, vacuum extractor). When the parturient approach complete cervical dilatation (8-10 cm), the anaesthetist must perform a last epidural injection for perineal analgesia. Generally a local anaesthetic is used (ex : Ropivacaine). Adjuvant can be associated to local anaesthetic (Sufentanil, Clonidine and more recently Neostigmine) to maximize local anaesthetic without increasing motor block. Neostigmine, a cholinesterase inhibitor, increase concentration of acetylcholine on synaptic level and stimulate analgesic mechanisms mediated by this acetylcholine on dorsal horn of spinal cord. Perineal pain after childbirth appears in most of the women with or without episiotomy. (Mac Arthur Am J Obst. Gynecol. 2004). This perineal pain can become source of chronic pain in 9%-12% of the cases. Neostigmine, a cholinesterase inhibitor at the dose of 500µg, combined with Sufentanil or Ropivacaine (=local anaesthetic) has an analgesic effect. The goal of this study is to examine the effect of epidural Neostigmine for perineal analgesia at the end of the labour and on the development of chronic pain post-partum. Inclusion criteria : any parturient of 18-45 years, normal pregnancy, at full term and having an effective epidural anaesthesia during labour. Exclusion criteria : multiple pregnancy, obstetric pathology, refusal of participation. Randomisation : 2 groups of 30 patients Method : Installation of the epidural catheter : \- Injection of Ropivacaïne + Sufentanil Perineal analgesia : * Ropi Group : epidural injection of Ropivacaine * Neostigmine Group : epidural injection of Ropivacaine and Neostigmine Evaluation of VAS, vital signs of parturient and fetal heart rate, instrumentation rate. Evaluation of immediate post-partum pain (48hours) and use of analgesic medication in the ward. Evaluation of chronic pain after 10 days and 1 month.

Interventions

DRUGneostigmine

Sponsors

Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* any parturient of 18-45 years * normal pregnancy * at full term * having an effective epidural anesthesia during labor

Exclusion criteria

* multiple pregnancy * obstetric pathology * refusal of participation

Design outcomes

Primary

MeasureTime frame
acute pain (VAS)
chronic pain (questionnaire)

Countries

Belgium

Contacts

Primary ContactFabienne Roelants, MD
Fabienne.Roelants@anes.ucl.ac.be02 764 18 21
Backup ContactPatricia Lavand'homme, MD, PhD
lavandhomme@anes.ucl.ac.be02 764 18 21

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026